Literature DB >> 14514779

Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.

K S G Cunha1, E P Barboza, E C Da Fonseca.   

Abstract

BACKGROUND: The hallmark of neurofibromatosis type 1 (NF1) is the development of multiple neurofibromas. Solitary neurofibroma may occur in an individual who does not have NF1, but multiple neurofibromas tend to develop only in those with NF1. It has been suggested that hormones may influence the neurofibromas of patients with NF1. The evidence that hormones may influence the growth of neurofibromas comes mainly from the observation that localised neurofibromas of patients with NF1 commonly grow during puberty and pregnancy. Because growth hormone (GH) concentrations increase during puberty, it is possible that GH influences the growth of these tumours. AIMS: To investigate the presence of GH receptors (GHRs) in neurofibromas.
METHODS: By means of immunohistochemistry, the presence of GHRs was investigated in two groups of patients: 16 patients without NF1 with solitary neurofibromas (group A) and 10 patients with NF1 with localised neurofibromas (group B).
RESULTS: Six of the 16 patients in group A had neurofibromas that were immunopositive for GHR, whereas nine of the 10 patients in group B were immunopositive.
CONCLUSIONS: Most patients with NF1 have localised neurofibromas that express GHR. This suggests that GH may play some role in the development of localised neurofibromas in patients with NF1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514779      PMCID: PMC1770079          DOI: 10.1136/jcp.56.10.758

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor.

Authors:  K K Kaulsay; T Zhu; W Bennett; K O Lee; P E Lobie
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

2.  Mouse tumor model for neurofibromatosis type 1.

Authors:  K S Vogel; L J Klesse; S Velasco-Miguel; K Meyers; E J Rushing; L F Parada
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

Review 3.  Molecular mechanism of growth hormone signalling.

Authors:  N Billestrup; J A Hansen; L H Hansen; A H Møldrup; E D Galsgaard; J H Nielsen
Journal:  Endocr J       Date:  1998-04       Impact factor: 2.349

4.  Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.

Authors:  L S Sherman; R Atit; T Rosenbaum; A D Cox; N Ratner
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

5.  Expression of growth hormone receptor in benign and malignant cutaneous proliferative entities.

Authors:  M Ginarte; T García-Caballero; V Fernández-Redondo; A Beiras; J Toribio
Journal:  J Cutan Pathol       Date:  2000-07       Impact factor: 1.587

6.  Leukemia in a patient treated with growth hormone.

Authors:  M Aktan; R Tanakol; M Nalçaci; G Dinçol
Journal:  Endocr J       Date:  2000-08       Impact factor: 2.349

Review 7.  SH2-B and SIRP: JAK2 binding proteins that modulate the actions of growth hormone.

Authors:  C Carter-Su; L Rui; M R Stofega
Journal:  Recent Prog Horm Res       Date:  2000

8.  Epidemiology of acromegaly in the Newcastle region.

Authors:  L Alexander; D Appleton; R Hall; W M Ross; R Wilkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1980-01       Impact factor: 3.478

9.  Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. British Prostate Study Group.

Authors: 
Journal:  Br J Urol       Date:  1979-10

10.  Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas.

Authors:  T García-Caballero; H M Mertani; A Lambert; R Gallego; M Fraga; E Pintos; J Forteza; M Chevallier; P E Lobie; B K Vonderhaar; A Beiras; G Morel
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

View more
  13 in total

1.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

2.  Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.

Authors:  Hua Li; Xuelian Zhang; Lauren Fishbein; Frederick Kweh; Martha Campbell-Thompson; George Q Perrin; David Muir; Margaret Wallace
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

3.  Progesterone and Estrogen Receptors in Neurofibromas of Patients with NF1.

Authors:  Mauro Geller; Spyros G E Mezitis; Fabio Pereira Nunes; Marcia G Ribeiro; Alexandra Prufer de Q C Araújo; Marcello D Bronstein; Rodrigo Siqueira-Batista; Andréia Patrícia Gomes; Lisa Oliveira; Karin Soares Gonçalves Cunha
Journal:  Clin Med Pathol       Date:  2008-09-15

4.  Receptor of ghrelin is expressed in cutaneous neurofibromas of individuals with neurofibromatosis 1.

Authors:  Rafaela E Rozza-de-Menezes; Nicolle C Gaglionone; Raquel M Andrade-Losso; Orlando H K Siqueira; Lilian M Almeida; Kamila da S Peruzini; Marco A C Guimarães-Filho; Carolina I Brum; Mauro Geller; Karin S Cunha
Journal:  Orphanet J Rare Dis       Date:  2017-12-20       Impact factor: 4.123

5.  Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.

Authors:  Su-Jin Park; Birgit Sawitzki; Lan Kluwe; Victor F Mautner; Nikola Holtkamp; Andreas Kurtz
Journal:  BMC Med       Date:  2013-04-23       Impact factor: 8.775

6.  Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival.

Authors:  Karin S G Cunha; Anabela C Caruso; Paulo A S de Faria; Licínio E da Silva; Andréa R C Pires; Mauro Geller; Vânia S Lopes; Rodrigo S de Moura-Neto
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

7.  Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.

Authors:  Deeann Wallis; Anat Stemmer-Rachamimov; Sarah Adsit; Bruce Korf; Dominique Pichard; Jaishri Blakeley; Kavita Y Sarin
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

8.  Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1.

Authors:  Karin Soares Gonçalves Cunha; Eliane Porto Barboza; Eliene Carvalho da Fonseca
Journal:  Clinics (Sao Paulo)       Date:  2008-02       Impact factor: 2.365

9.  Initial Exploration on Temporal Branch of Facial Nerve Function Preservation in Plexiform Neurofibroma Resection.

Authors:  Xiaojie Hu; Melia Bogari; Andy Tan; Xiaoyan Gao; Yang Gao; Hui Chen; Wei Li; Yunbo Jin; Gang Ma; Xiaoxi Lin
Journal:  J Craniofac Surg       Date:  2016-09       Impact factor: 1.046

Review 10.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.